|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 March 2002, Vol. 99, No. 6, pp. 1952-1958
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Prognostic significance and modalities of flow cytometric minimal
residual disease detection in childhood acute lymphoblastic
leukemia
Michael N. Dworzak,
Gertraud Fröschl,
Dieter Printz,
Georg Mann,
Ulrike Pötschger,
Nora Mühlegger,
Gerhard Fritsch, and
Helmut Gadner for the Austrian
Berlin-Frankfurt-Münster Study Group
From the Children's Cancer Research Institute, St Anna
Kinderspital, Vienna, Austria.
Detection of minimal residual disease (MRD) in acute lymphoblastic
leukemia (ALL) predicts outcome. Previous studies were invariably based
on relative quantification and did not investigate sample-inherent
parameters that influence test accuracy, which makes comparisons and
clinical conclusions cumbersome. Hence, we conducted a prospective,
population-based MRD study in 108 sequentially recruited children with
ALL uniformly treated with the ALL-Berlin-Frankfurt-Münster
(ALL-BFM) 95 protocol in Austria (median follow-up of 40 months). Using
sensitive, limited antibody panel flow cytometry applicable to 97% of
patients, we investigated 329 bone marrow samples from 4 treatment time
points. MRD was quantified by blast percentages among nucleated cells
(NCs) and by absolute counts (per microliter). Covariables such as NC
count, normal B cells, and an estimate of the test sensitivity were
also recorded. Presence and distinct levels of MRD correlated with a
high probability of early relapse at each of the time points studied.
Sequential monitoring at day 33 and week 12 was most useful for
predicting outcome independently from clinical risk groups: patients
with persistent disease ( 1 blast/µL) had a 100% probability of
relapse, compared to 6% in all others. Absolute MRD quantification was
more appropriate than relative, due to considerable variations in total
NC counts between samples. Regeneration of normal immature B cells
after periods of rest from treatment limited the test sensitivity. In
conclusion, MRD detection by flow cytometry is a strong and independent
outcome indicator in childhood ALL. Standardization regarding absolute
quantification on the basis of NCs and assessment during periods of
continuous treatment promise to increase the accuracy, simplicity, and
cost efficiency of the approach.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Stanulla and A. Schrauder
Bridging the gap between the north and south of the world: the case of treatment response in childhood acute lymphoblastic leukemia
Haematologica,
June 1, 2009;
94(6):
748 - 752.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Irving, J. Jesson, P. Virgo, M. Case, L. Minto, L. Eyre, N. Noel, U. Johansson, M. Macey, L. Knotts, et al.
Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting;
Haematologica,
June 1, 2009;
94(6):
870 - 874.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. N. Dworzak, A. Schumich, D. Printz, U. Potschger, Z. Husak, A. Attarbaschi, G. Basso, G. Gaipa, R. Ratei, G. Mann, et al.
CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy
Blood,
November 15, 2008;
112(10):
3982 - 3988.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Borowitz, M. Devidas, S. P. Hunger, W. P. Bowman, A. J. Carroll, W. L. Carroll, S. Linda, P. L. Martin, D. J. Pullen, D. Viswanatha, et al.
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study
Blood,
June 15, 2008;
111(12):
5477 - 5485.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bottcher, M. Ritgen, S. Buske, S. Gesk, W. Klapper, E. Hoster, W. Hiddemann, M. Unterhalt, M. Dreyling, R. Siebert, et al.
Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations
Haematologica,
April 1, 2008;
93(4):
551 - 559.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Zhou, M. A Goldwasser, A. Li, S. E. Dahlberg, D. Neuberg, H. Wang, V. Dalton, K. D McBride, S. E. Sallan, L. B Silverman, et al.
Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01
Blood,
September 1, 2007;
110(5):
1607 - 1611.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Choi, M. J. Henderson, E. Kwan, A. H. Beesley, R. Sutton, A. Y. Bahar, J. Giles, N. C. Venn, L. D. Pozza, D. L. Baker, et al.
Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone
Blood,
July 15, 2007;
110(2):
632 - 639.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Raff, N. Gokbuget, S. Luschen, R. Reutzel, M. Ritgen, S. Irmer, S. Bottcher, H.-A. Horst, M. Kneba, D. Hoelzer, et al.
Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials
Blood,
February 1, 2007;
109(3):
910 - 915.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Bruggemann, T. Raff, T. Flohr, N. Gokbuget, M. Nakao, J. Droese, S. Luschen, C. Pott, M. Ritgen, U. Scheuring, et al.
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia
Blood,
February 1, 2006;
107(3):
1116 - 1123.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Jabbour, S. Faderl, and H. M. Kantarjian
Adult Acute Lymphoblastic Leukemia
Mayo Clin. Proc.,
November 1, 2005;
80(11):
1517 - 1527.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Stanulla, E. Schaeffeler, T. Flohr, G. Cario, A. Schrauder, M. Zimmermann, K. Welte, W.-D. Ludwig, C. R. Bartram, U. M. Zanger, et al.
Thiopurine Methyltransferase (TPMT) Genotype and Early Treatment Response to Mercaptopurine in Childhood Acute Lymphoblastic Leukemia
JAMA,
March 23, 2005;
293(12):
1485 - 1489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Pui, M. Schrappe, R. C. Ribeiro, and C. M. Niemeyer
Childhood and Adolescent Lymphoid and Myeloid Leukemia
Hematology,
January 1, 2004;
2004(1):
118 - 145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Li, J. Zhou, D. Zuckerman, M. Rue, V. Dalton, C. Lyons, L. B. Silverman, S. E. Sallan, and J. G. Gribben
Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection
Blood,
December 15, 2003;
102(13):
4520 - 4526.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-B. Vidriales, J. J. Perez, M. C. Lopez-Berges, N. Gutierrez, J. Ciudad, P. Lucio, L. Vazquez, R. Garcia-Sanz, M. C. del Canizo, J. Fernandez-Calvo, et al.
Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value
Blood,
June 15, 2003;
101(12):
4695 - 4700.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Moppett, G A A Burke, C G Steward, A Oakhill, and N J Goulden
The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia
J. Clin. Pathol.,
April 1, 2003;
56(4):
249 - 253.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Hoelzer, N. Gokbuget, O. Ottmann, C.-H. Pui, M. V. Relling, F. R. Appelbaum, J. J.M. van Dongen, and T. Szczepanski
Acute Lymphoblastic Leukemia
Hematology,
January 1, 2002;
2002(1):
162 - 192.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
